MYELODYSPLASTIC SYNDROMES
Clinical trials for MYELODYSPLASTIC SYNDROMES explained in plain language.
Never miss a new study
Get alerted when new MYELODYSPLASTIC SYNDROMES trials appear
Sign up with your email to follow new studies for MYELODYSPLASTIC SYNDROMES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental INKmune therapy for blood cancers halted after just 2 patients
Disease control TerminatedThis early-stage study tested an experimental drug called INKmune in people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The goal was to find a safe dose and check for side effects. However, the study was stopped early after only 2 people enrolled, so no c…
Matched conditions: MYELODYSPLASTIC SYNDROMES
Phase: PHASE1 • Sponsor: Inmune Bio, Inc. • Aim: Disease control
Last updated Jun 16, 2026 22:33 UTC
-
Experimental antibody targets Hard-to-Treat leukemia, but early trial halted
Disease control TerminatedThis early-phase study tested a new drug called gentulizumab in 58 adults with acute myeloid leukemia or myelodysplastic syndrome that had come back or stopped responding to treatment. The drug works by blocking a protein on cancer cells to help the immune system attack them. The…
Matched conditions: MYELODYSPLASTIC SYNDROMES
Phase: PHASE1 • Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 16, 2026 22:22 UTC
-
Experimental combo for tough blood cancers shows early promise but trial halted
Disease control TerminatedThis early-phase study tested a new drug called DSP107 combined with standard treatments for people with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML) that had come back or not responded to prior therapy. The goal was to f…
Matched conditions: MYELODYSPLASTIC SYNDROMES
Phase: PHASE1 • Sponsor: Kahr Medical • Aim: Disease control
Last updated Jun 16, 2026 22:22 UTC
-
New hope for MDS patients? study tests MBG453 combo but ends early
Disease control TerminatedThis study tested adding an experimental drug called MBG453 to standard chemotherapy for people with a serious bone marrow disorder called myelodysplastic syndrome (MDS). The trial included 127 adults with high-risk MDS who could not have a stem cell transplant. The goal was to s…
Matched conditions: MYELODYSPLASTIC SYNDROMES
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 16, 2026 12:52 UTC
-
Blood cancer anemia drug study halted early
Disease control TerminatedThis study tested a new drug called INCB000928 for people with anemia caused by myelodysplastic syndromes (MDS) or multiple myeloma. It was open to those who needed blood transfusions or had anemia symptoms. The study aimed to find a safe dose and check for side effects, but it w…
Matched conditions: MYELODYSPLASTIC SYNDROMES
Phase: PHASE1, PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 15, 2026 19:09 UTC
-
Immune cell therapy shows promise for tough leukemia cases
Disease control TerminatedThis study tested a treatment called TCB008, made from donated immune cells, for adults with acute myeloid leukemia (AML) that came back or didn't respond to standard therapy. The goal was to see if it could reduce cancer cells in the bone marrow. The trial was stopped early, but…
Matched conditions: MYELODYSPLASTIC SYNDROMES
Phase: PHASE2 • Sponsor: TC Biopharm • Aim: Disease control
Last updated Jun 15, 2026 19:09 UTC
-
Promising combo for blood cancers fails to finish trial
Disease control TerminatedThis study tested whether adding MBG453 to standard azacitidine could help adults with serious bone marrow diseases (MDS or CMML-2) live longer. About 530 participants were planned, but the trial was stopped early. The goal was disease control, not a cure, since patients were not…
Matched conditions: MYELODYSPLASTIC SYNDROMES
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC
-
Experimental leukemia drug trial halted early
Disease control TerminatedThis early-stage study tested a new drug called CC-95251, alone or with other cancer drugs, in people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) that had come back or not responded to treatment. The main goals were to check safety and find the right dose…
Matched conditions: MYELODYSPLASTIC SYNDROMES
Phase: PHASE1 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC
-
Early-Stage drug combo study for MDS halted
Disease control TerminatedThis study tested combinations of drugs in 33 adults with lower-risk myelodysplastic syndrome (MDS), a blood disorder. The main goal was to check safety and find the right doses. The trial was ended early, so results are limited.
Matched conditions: MYELODYSPLASTIC SYNDROMES
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC
-
Experimental blood cancer drug trial halted early
Disease control TerminatedThis study tested a new drug called SAR443579 in adults and children with certain blood cancers that had come back or not responded to treatment. The goal was to see if the drug was safe and could shrink or control the cancer. The trial was stopped early, so results are limited.
Matched conditions: MYELODYSPLASTIC SYNDROMES
Phase: PHASE1, PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 15, 2026 19:05 UTC
-
Experimental cancer drug trial halted early
Disease control TerminatedThis early-phase study tested a new drug called AUR103 Calcium in 27 adults with advanced solid tumors, acute myeloid leukemia, myelodysplastic syndromes, or non-Hodgkin lymphoma who had no other treatment options. The goal was to find the best dose and check safety. The study wa…
Matched conditions: MYELODYSPLASTIC SYNDROMES
Phase: PHASE1 • Sponsor: Aurigene Discovery Technologies Limited • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC
-
Experimental combo therapy for MDS and AML shows early promise but study halted
Disease control TerminatedThis early-stage trial tested a new drug called SL-172154, given alone or with standard chemotherapy drugs (azacitidine and venetoclax), in adults with high-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The goal was to check safety and find the best dose. T…
Matched conditions: MYELODYSPLASTIC SYNDROMES
Phase: PHASE1 • Sponsor: Shattuck Labs, Inc. • Aim: Disease control
Last updated Jun 11, 2026 12:10 UTC
-
MDS drug trial halted early after only 2 patients enrolled
Disease control TerminatedThis study tested a new drug called BMS-986253 for people with myelodysplastic syndromes (MDS), a group of bone marrow cancers. The goal was to see if the drug was safe and effective, either alone or with another treatment. Only 2 adults joined before the study was stopped early,…
Matched conditions: MYELODYSPLASTIC SYNDROMES
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 09, 2026 12:09 UTC
-
Promising MDS drug trial cut short – only 10 patients enrolled
Disease control TerminatedThis study tested a drug called MBG453 in people with a bone marrow disease called myelodysplastic syndromes (MDS) that had not responded to other treatments. The goal was to see if the drug could improve blood cell counts and reduce the need for transfusions. The trial was stopp…
Matched conditions: MYELODYSPLASTIC SYNDROMES
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 09, 2026 12:07 UTC
-
New cell therapy aims to stop transplant complications in blood cancer patients
Disease control TerminatedThis early-phase study tested whether a special type of cell (interferon gamma-primed mesenchymal stromal cells) could be safely given to prevent graft-versus-host disease, a common and serious complication after bone marrow transplant. Only 4 patients with acute leukemia or myel…
Matched conditions: MYELODYSPLASTIC SYNDROMES
Phase: PHASE1 • Sponsor: Edwin Horwitz • Aim: Disease control
Last updated Jun 03, 2026 12:02 UTC
-
New pill combo aims to fight tough bone marrow cancer
Disease control TerminatedThis study tested two oral drugs, eltanexor and Inqovi, in adults with high-risk myelodysplastic syndromes (MDS) that did not improve with standard treatment. MDS is a bone marrow disorder that can lead to leukemia. The goal was to find a safe dose and see if the combination help…
Matched conditions: MYELODYSPLASTIC SYNDROMES
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 01, 2026 17:58 UTC
-
Leukemia drug study tests pill form against IV, but stops early
Knowledge-focused TerminatedThis study aimed to see if an oral (pill) form of the drug cladribine works as well as the standard IV (intravenous) form in people with certain blood cancers like leukemia. Only 3 people took part before the study was stopped early. The main goal was to check safety and how the …
Matched conditions: MYELODYSPLASTIC SYNDROMES
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 05, 2026 12:06 UTC